Stephen Kimmel, MD, MSCE is the founding Director of CTER. He received his A.B. from Princeton University, his M.D. from New York University School of Medicine, and a Master of Science in Clinical Epidemiology from the University of Pennsylvania School of Medicine. He is a Professor of Medicine in the Cardiovascular Division, a Professor of Epidemiology in the Department of Biostatistics and Epidemiology, and Acting Director, Division of Clinical Epidemiology and the Clinical Epidemiology Unit (CEU), Center for Clinical Epidemiology and Biostatistics (CCEB) and of the Epidemiology Division of the Department of Biostatistics and Epidemiology. Dr. Kimmel's research focuses on interventions to improve medical treatments, including adherence and pharmacogenetic interventions.
Madeline "Lynn" Alexander, PhD, is the Managing Director of CTER. She received her B.A. from Boston College and her Ph.D. in psychology from Columbia University. Lynn has spent most of her career at Penn, first as a faculty member in the Department of Psychiatry and, before joining CTER and the CCEB, as Regulatory Compliance Officer in the Office of the Vice Provost for Research. She has many years of experience overseeing research in the areas of diagnostic and outcomes assessment, behavioral and pharmacological interventions, and psychiatric genetics.
Sandy Barile is the Administrative Coordinator of CTER. She has been at Penn, working in the CCEB, for the past 16 years. Sandy has extensive experience coordinating large center grants and multi-investigator research projects.
Chief Medical Officer & Sr. VP for UPHS
As Chief Medical Officer and Sr. Vice-President for the Penn Health System, Dr. Brennan oversees the development of strategy related to healthcare quality and safety activities, implementation and measurement. He develops health policy related to patient safety, pharmaceutical industry relations and public disclosure of healthcare associated infections. Dr. Brennan previously directed infection control for the Health System and the Tuberculosis Control Program of the City of Philadelphia Department of Public Health. His clinical interests include healthcare associated infections, public reporting, tuberculosis, and nosocomial infections and he attends on the Infectious Diseases Consultation Service. From 2003-2010, he chaired HICPAC, the Healthcare Infection Control Practices Advisory Committee for the CDC and the Department of Health and Human Services. He also chaired The Sentinel Event Advisory Group (now the Patient Safety Advisory Group) for The Joint Commission. He is the chair-designate of the southeastern Pennsylvania Health Care Improvement Foundation.
Professor of Medicine and Epidemiology; Interim Chair, Dept. of Clinical Epidemiology and Biostatistics (CCEB)
Dr. Feldman serves as Interim Director for the Center for Clinical Epidemiology and Biostatistics and Interim Chair for the Department of Biostatistics and Epidemiology. He is a nationally and internationally recognized leader in renal epidemiology and is an award winning teacher who has made exemplary contributions to undergraduate and graduate medical education. Dr. Feldman's major research interests address the epidemiology of kidney diseases with a particular focus on the management of kidney disease from the stage of chronic kidney dysfunction to end-stage renal disease. He leads Penn-based researchers and several national research groups addressing various manifestations and treatment of kidney disease. These research programs address the causes of failure of vascular accesses used for hemodialysis, anemia and metabolic disorders of kidney disease, the determinants of long-term survival of kidney allografts, the epidemiology of drug-related kidney disease, the relationship of ethnicity and kidney disease, the inter-relationship between chronic kidney disease and cardiovascular disease, and pediatric kidney diseases. Dr. Feldman is the national study chair of the NIH/NIDDK's Hemodialysis Fistula Maturation Cohort Study and its Chronic Renal Insufficiency Cohort Study (CRIC) whose scientific and data coordinating he leads as Principal Investigator at Penn.
George A. Weiss University Professor, Professor of Epidemiology and Nursing
Dr. Glanz is George A. Weiss University Professor, Professor of Epidemiology and Nursing and Director of the Center for Health Behavior Research at the University of Pennsylvania. Her research focuses on cancer prevention and control, theories of health behavior, obesity and the built environment, social and health policy, and new health communication technologies. She is currently conducting research on skin cancer prevention, nutrition and chronic disease prevention, compliance with glaucoma medications, and colorectal cancer screening. Dr. Glanz is a member of the Task Force on Community Preventive Services, a federally-appointed task force that oversees the Community Guide evidence reviews. Her scholarly contributions consist of more than 360 journal articles and book chapters. Dr. Glanz is senior editor of Health Behavior and Health Education: Theory, Research, and Practice (Jossey-Bass Inc., 1990, 1996, 2002, 2008), a widely used text currently in its fourth edition.
Professor of Biostatistics (PSOM) & Statistics (Wharton); Director, Biostatistics Division of CCEB
Dr. Landis serves as Director of the Biostatistics Unit within the Center for Clinical Epidemiology and Biostatistics (CCEB), and faculty Co-Director of the Clinical Research Computing Unit (CRCU), a designated core research facility providing clinical research informatics (CRI) collaboration and services for clinical and translational research investigators at Penn. Dr. Landis is PI of the Data Coordinating Core (DCC) for NIDDK's "Multidisciplinary Approach to Pelvic Pain (MAPP) Research Network" (2008-13), and Co-PI for NIDDK's adult "Chronic Renal Insufficiency Cohort (CRIC) Research Network." He also serves as Co-Director for the CTSA-funded "Center for Biomedical Informatics in Translation (BIIT)" (2006-11), promoting CRI best practices across the entire research spectrum of the Penn Medicine and CHOP enterprises, and Core Director for the Abramson Cancer Center's Biomedical Data Coordination Core (BDCC). For more than forty years, he has been actively involved in collaborative biomedical research, and the development and evaluation of methods for the analysis of categorical data. His methodological research interests are in the analysis of categorical data, particularly statistical methods for repeated measurement and longitudinal categorical data, clinical trials, epidemiological studies, complex sample surveys and applications to cardiovascular, ophthalmology, respiratory, psychiatric, renal and urological research.
Mary W. Calkin Professor of Psychiatry and Annenberg Public Policy Center
Dr. Lerman is the Mary W. Calkins Professor in the Department of Psychiatry and the Annenberg Public Policy Center at the University of Pennsylvania. She is also Director of Penn’s NIH-funded Center for Interdisciplinary Research on Nicotine Addiction, and the Deputy Director of the Abramson Cancer Center. Dr. Lerman’s research interests focus on nicotine addiction pharmacogenetics and medication development. Over a decade ago, she was among the first to publish evidence for genetic influences on smoking behavior and to study genetic modifiers of response to pharmacotherapy for nicotine addiction. Her recent work incorporates neuroimaging technologies to elucidate the neural substrates of nicotine addiction and to validate neuroimaging biomarkers for risk stratification and targeted therapy. The ultimate goal of her research program is to translate these findings to clinical practice in the form of personalized medicine for smoking cessation. Dr. Lerman’s awards and honors include membership in the Institute of Medicine of the National Academies, the American Psychological Association Award for Outstanding Contributions to Health Psychology, the American Society of Preventive Oncology (ASPO) Cullen Award for Tobacco Research, and the Alton Ochsner Award for Research Relating Tobacco and Health. She is a past President of the Society for Research on Nicotine and Tobacco, the primary international society for nicotine addiction scientists. Dr. Lerman serves on the National Institute on Drug Abuse Advisory Council, and is a former member of the National Cancer Institute Board of Scientific Advisors and the National Advisory Council for Human Genome Research. She has over 320 publications and has been the Principal Investigator on 11 R01s, a U01, and a Transdisciplinary Tobacco Use Research Center P50 grant, which is now in its 14th year.
Professor and Chair, Department of Medicine
Dr. Shannon is the Frank Wister Thomas Professor of Medicine at the Perelman School of Medicine and Chairman of the Department of Medicine of the University of Pennsylvania Health System. His investigative interests are in the area of myocardial metabolism. Currently, his work focuses on incretin hormone biology in cardiovascular disease. Dr. Shannon has performed pioneering work in patient safety, and he has served as a mentor for the Institute for Healthcare Improvement (IHI). His work on patient safety was recently a centerpiece for the PBS feature entitled "Remaking American Medicine." He also sits on the Governor’s Special Panel on Patient Safety and is a member of the Technical Advisory Group of the Pennsylvania Healthcare Cost Containment Council. He has served as a consultant to the Delmarva Foundation, The Safest in America Consortium, Blue Cross/Blue Shield of Massachusetts, the New York City Business Group on Health, and the US House of Representatives Committee on Energy and Commerce.
Professor of Medicine & Health Care Management (Wharton)
Dr. Volpp is the Director of the Center for Health Incentives and Behavioral Economics of the Leonard Davis Institute, Director of the Penn CMU Roybal P30 Center in Behavioral Economics and Health, a staff physician at the Philadelphia VA Medical Center, and Professor of Medicine and Health Care Management at the School of Medicine and the Wharton School at the University of Pennsylvania. His work focuses on developing and testing innovative ways of applying insights from behavioral economics in improving patient health behavior and affecting provider performance. He has done work with a variety of employers and insurers and health systems testing the effectiveness of financial incentives in addressing tobacco dependence, obesity, and medication non-adherence as well as how policy reforms affect hospital quality. These studies have been funded by the National Institutes of Aging as well as the National Heart Lung, Blood Institute; the National Cancer Institute; the National Institute of Diabetes and Digestive and Kidney Disorders; the CDC;VA Health Services Research and Development; the US Department of Agriculture; Robert Wood Johnson Foundation; the Hewlett Foundation; the Commonwealth Foundation; the Aetna Foundation; Mckinsey; CVS Caremark; Horizon Blue Cross Blue Shield; Aramark; and Discovery (South Africa). He is an elected member of the Institute of Medicine of the National Academy of Sciences.
Professor of Medicine
As Chief and Program Director of the Section of Allergy and Immunology, Division of Pulmonary Allergy Critical Care Medicine, Dr. Apter's research has focused on improving asthma outcomes for low income urban adults. She has conducted observational and intervention studies examining adherence and health literacy with the goals of improving access to care and patient-provider communication.
Professor of Medicine
Dr. Armstrong directs a long-standing research program at Penn using clinical and health services research to examine the translation of genomic medicine into clinical practice. Her research focuses on medical decision-making and the utilization and outcomes of genetic testing. For example, she has identified disparities in the use of BRCA1/2 testing between African-American and White women with a family history of breast or ovarian cancer. Subsequent research has suggested this disparity may be driven by patient distrust or differences in providers seen by African American and White women. She currently serves as PI on two breast cancer implementation projects.
Associate Professor of Family Medicine and Community Health (PSOM) and Anthropology (SAS)
As a medical anthropologist and Co-director of the Mixed Methods Research Lab, Dr. Barg works with interdisciplinary research teams across six schools at Penn to incorporate qualitative and mixed methods research into patient-centered research paradigms. She has investigated patient perceptions, adherence to treatment, and treatment choices in the areas of depression, contraception, ADHD, and weight gain. She is co-PI with Dr. Stephen Kimmel on the PCORI-funded pilot project, “Patient and Provider Perspectives on Hospital Readmissions.” This study uses mixed methods to understand factors affecting control of congestive heart failure from the patient's perspective.
Professor of Pediatrics
Dr. Barrett's research interest is focused on investigating sources of variation in pharmacokinetics and pharmacodynamics applying clinical pharmacologic investigation coupled with modeling and simulation strategies to pursue rational dosing guidance. He develops pharmacometric approaches to advance PK/PD, medical informatics, and disease progression modeling. Dr. Barrett has also integrated model-based decision support systems with hospital electronic medical records and pioneered the pediatric knowledgebase development program for the past 6 years. He is actively involved with creating cell signaling models and disease progression models for spinal muscular atrophy (SMA).
Clinical Professor of Medicine
Barbara Bernhardt is a genetic counselor and social sciences researcher in the Department of Medicine at the University of Pennsylvania. She currently co-directs the Penn Center for the Integration of Genetic Healthcare Technologies which is one of the 6 NIH-funded Centers of Excellence in ELSI research in the United States. For several decades, Ms. Bernhardt has conducted both qualitative and quantitative research exploring ethical and social issues relating to the diffusion of new genetic technologies, and the influence of the media, patients, providers, third party payers, and clinical practice guidelines on the offering and utilization of genetic tests and services. Her current research projects include an investigation of the impact of the uncertainties of prenatal microarray testing on patients and providers; an evaluation of the offering of whole exome sequencing to children; and an assessment of the clinical utility of genomic testing for risk of common complex disorders.
Assistant Professor of Epidemiology and Biostatistics & Family Medicine and Community Health
Dr. Bogner's prior work underscores the importance of addressing depression in patients with diabetes in order to improve outcomes for both conditions. She has employed the latent class model to classify older patients according to the pattern of antidepressant adherence over time, studied co-morbidity of depression in older primary care patients with diabetes and CVD, assessed depression in community settings, examined the role of gender and ethnicity in expression of depression, studied the link between cognitive decline and depression identification and management, executive dysfunction, depressive disorder and mortality, examined methodological issues in primary care research, and specifically focused on integration of mental health care into primary care settings. She now has a R01 award to study trajectories of depressive symptoms and medical comorbidity in relation to the outcomes of major depression and suicidal ideation at 2 years. In addition, her grant funding from the American Diabetes Association and the American Heart Association focuses on depression in older adults with diabetes and cardiovascular disease, the goal of which has been to develop treatment for depression that is integrated with the treatment of chronic conditions such as diabetes. Dr. Bogner was awarded a pilot grant from CTER to study the feasibility and effectiveness of delivery of integrated intervention strategies by licensed practical nurses working in primary care settings.
Professor of Communication, Annennberg School of Communication
Dr. Cappella's research focuses broadly on theory and research about the design of messages to achieve specific behavioral goals -- in health, risk, and related contexts. For the past 10 years, he has been working in the area of cancer communications exclusively. The research generally focuses on the way that health messages should be designed to maximize their effectiveness and minimize the inadvertent harm they might bring. This has led to studies on the role of genetic risk information and its implications for engaging and undermining healthy behaviors; effective anti-smoking messages; narrative forms as a means to engage audiences; and a wide variety of structural and content factors that can enhance and retard effectiveness. His studies have produced valid, reliable, and efficient measures of message effectiveness; techniques for evaluating the strength of arguments presented in messages, and techniques for objectively coding a wide variety of non-content message features pertinent to their success. His approach is highly quantitative, employs large, representative samples, seeks to insure that findings are robust (replicable), and statistically secure. Dr. Cappella's work has been published in the literatures of both communication and cancer prevention (specifically anti-smoking messages) and has been funded by the National Cancer Institute, the National Human Genome Research Institute, the CDC, NIDA and other groups. He has collaborated extensively with others on the PENN campus and elsewhere around the country. Projects relate to cancer prevention and control and in some instances to coping post treatment (breast cancer). All of his research is explicitly concerned with the features of messages and how those features enhance or retard the effectiveness of communications about cancer.
Assistant Professor of Emergency Medicine and Epidemiology
Dr. Carr serves as the Associate Director of the Division of Emergency Care Policy & Research and the curriculum director for the emergency care research fellowship at Penn. His research focuses on understanding how the organization of emergency care impacts outcomes for time critical conditions and how new models of dissemination and implementation of best practices can improve outcomes for unplanned critical illness. Dr. Carr and his colleagues were awarded a pilot grant from CTER to test the feasibility of encouraging compliance with Early Goal Directed Therapy (EGDT) for sepsis via telemedical interface in the emergency department.
Professor of Biostatistics
Dr. Jonas H Ellenberg has worked extensively in large scale clinical studies, both observational and controlled with major design interests in reducing selection bias in diverse areas of medical research. His primary interests are effectiveness clinical trials; the combination of data from clinical trials and observational studies in comparative effectiveness studies; and measures of adherence and approaches to its enhancement.
Professor of Biostatistics
Dr. Ellenberg's research interests have focused on issues in the design and analysis of clinical trials, and assessment of medical product safety. Particular areas of interest include efficient trial designs, interim monitoring and the operation of data monitoring committees, evaluation of surrogate endpoints, ethical issues in clinical research, and special issues in trials of cancer and AIDS therapies, and of vaccines. She serves as Chair of the Board of Trustees for the National Institute of Statistical Sciences beginning in 2011. Her book on clinical trials data monitoring committees, co-authored with Drs. Thomas Fleming (University of Washington) and David DeMets (University of Wisconsin), was named Wiley Europe Statistics Book of the Year for 2002.
Professor, School of Social Policy and Practice
Dr. Gellis directs the Center for Mental Health & Aging at the University of Pennsylvania. He is a Hartford National Faculty Scholar and an expert in geriatric mental health services research. His primary area of focus is on late life depression, telehealth technology, and integrated health and mental health services. He conducts rigorous applied research in home health and behavioral health settings. His research has contributed to efforts to improve depression care for homebound medically ill older adults who are recipients of telehealth and home health care.
Associate Professor of Medicine/Infectious Disease and Epidemiology
Dr. Gross is board certified in Infectious Diseases and Epidemiology and is a tenured Associate Professor of Medicine in the Division of Infectious Diseases and Associate Professor of Epidemiology in the Department of Biostatistics and Epidemiology at the University of Pennsylvania where he is a Senior Scholar (core faculty) in the Center for Clinical Epidemiology and Biostatistics. His research is focused on outcomes with antiviral therapy for HIV and hepatitis viruses in both the developed and developing worlds. A particular interest is the issue of adherence to antiviral therapy. He has been either principal investigator or co-investigator on five adherence intervention trials using diverse modalities such as directly observed therapy, partner-support training, narcotic antagonists in heroin addicts, and problem solving approaches to adherence barriers. One of the interventions is an AIDS Clinical Trials Group multinational study with several sites in sub-Saharan Africa for which he is Protocol Chair. He is also PI of a large cohort study in Botswana assessing the impact of pharmacogenetics on HIV treatment outcomes.
Associate Professor of Family and Community Health, School of Nursing
Dr. Hanrahan has been researching innovative models of integrated physical and mental health care for individuals who have a serious mental illness. As a co-investigator for an NIH funded RCT, from 2004-2008 she developed and implemented a nurse practitioner home-based model of care for individuals with serious mental illness (SMI) and HIV. As a principal investigator for a Robert Wood Johnson Foundation funded pilot RCT, her research team studied the feasibility of a transitional care model where a nurse practitioner followed a patient from the hospital to home for 90 days. They monitored readmission, links to community providers and medication as the outcomes. These studies led Dr. Hanrahan to seek technology approaches to research because so much of the SMI individual's outcomes interface with the urban ecology and social determinants of health. Currently, she is working with systems engineer, Barry Silverman, PhD, to build a simulated urban mental health operation (SUMO) using agent-based models. Additionally, she is studying a videography approach to elicit the voice of a person with serious mental illness as they recover. The videography will be used to build authentic agent-based models for SUMHO that represent a patient-centered view.
Associate Professor of Biostatistics and Epidemiology
Dr. Hennessy's research program in pharmacoepidemiology focuses on drug-drug interactions and comparative drug safety more broadly. In addition to his research, Dr. Hennessy leads a program to improve medication use in the outpatient setting within the University of Pennsylvania Health System. He is also the Founding Director of the Center for Pharmacoepidemiology Research and Training (CPeRT) of the Center for Clinical Epidemiology and Biostatistics (CCEB).
Professor of Biostatistics and Epidemiology
Dr. Joffe's research centers on statistical methods for estimating the causal effects of time-varying treatments and exposures in epidemiology and medicine. Dr. Joffe is the Principal Investigator of an NIH-funded R01 on Selective and Future Ignorability in Causal Inference; the project seeks to understand how standard assumptions for causal inference can be relaxed where appropriate and so yield valid estimates of causal effects when standard assumptions are not appropriate.
Assistant Professor of Psychiatry
Dr. Kim's research and clinical expertise is in the area of perinatal psychiatry. She is interested in understanding the pathophysiology and treatment of mood and anxiety disorders during pregnancy in terms of both the health of the mother and her fetus. Unfortunately, most pregnant women do not get adequate treatment for their mental illness during pregnancy. Dr. Kim was awarded a pilot grant from CTER to evaluate whether computerized Cognitive Behavioral Therapy will enhance the acceptability and feasibility of depression treatment for pregnant women. Since perinatal psychiatry has a small number of "experts," Dr. Kim is interested in expanding the ability for pregnant women with mental illness to get appropriate counseling and treatment. This could occur by offering more acceptable treatments, enhancing education to clinicians and patients, and removing identified barriers to treatment.
Professor of Medicine
Dr. Lewis has been actively involved in clinical and translational research since 1996 and has substantial experience in evaluating the epidemiology and treatment of a broad range of gastrointestinal diseases, with a particular focus on inflammatory bowel disease. He has conducted numerous studies related to the safety of therapies for inflammatory bowel disease, the natural history of the disease, and both the efficacy and effectiveness of medical therapies. His research experience includes the conduct of cohort studies, case-control studies, meta-analysis, decision modeling, single and multi-center clinical trials, controlled feeding experiments, and observational nutritional epidemiology studies. Dr. Lewis also have extensive experience using data from large electronic medical record and administrative databases such as THIN, GPRD, Medicare, Medicaid, and Kaiser Permanente.
Professor of Psychology in Psychiatry
Dr. McKay's work has focused on the development and evaluation of disease management strategies for alcohol and cocaine use disorders. These studies have been done in publicly funded outpatient addiction treatment programs in Philadelphia, with patients who have chronic forms of these disorders, often with co-occurring psychiatric and medical problems. The studies have generally involved comparing two or more approaches to continuing care, or comparing treatment as usual in the programs against treatment as usual augmented by an extended recovery support intervention. His team has found that poor progress toward the initial goals of these treatment programs– particularly failure to achieve abstinence in the first few weeks of treatment– can be used to identify patients who are most likely to benefit from extended continuing care efforts. He has also done work on adaptive treatment interventions for addictions. Some of this work has been supported by an NIAAA P01 Center grant on adaptive treatment for alcoholism. In this center, his team is conducting several studies that use sequential randomization to construct optimal treatment algorithms and examine the impact of patient choice on outcomes. Currently, he is interested in developing effective strategies to treat and manage substance use disorders within primary care, as many individuals with these disorders do not want traditional addiction specialty care treatment. This will require patient-centered approaches that are tailored to the clinical needs and preferences of the patients, and are responsive to changes in patient status and symptoms over time.
Associate Professor of Biostatistics
Dr. Mitra's primary research interest is in statistical genetics where she has worked extensively on single nucleotide polymorphism (SNP) and haplotype problems in the context of family-based and population-based association studies. Dr. Mitra has collaborated with investigators in a number of medical areas, including clinical genetics and oncology. Specifically she has worked on studies that have investigated genetic associations in melanoma, colon cancer, and ovarian cancer, and has led the analysis of genome-wide association and deep-sequencing studies of testicular germ cell tumors. She has also worked on population-based outcomes and cost-effectiveness studies using SEER-Medicare data in the areas of colon, prostate, and bladder cancer.
Professor of Medicine & Healthcare Management (Wharton)
Dr. Polsky's research areas include health insurance and financial access to health care, economic evaluation of medical and behavioral health interventions, and the health care workforce. In 2007-08 he was the Senior Economist on health issues at the President’s Council of Economic Advisers.
Professor of Medicine & Genetics
Dr. Pyeritz directs an NHGRI-funded Center of Excellence in ELSI, the University of Pennsylvania Center for Integration of Genetic and Healthcare Technologies (Penn CIGHT). This center brings together scholars and trainees from diverse fields who study how new technologies are being evaluated and incorporated into medical care and health preservation. The goal is to inform policy decisions for the health system, the health professions, and the insurance industry. He also conducts research on genetic factors that predispose to cardiovascular diseases, especially those affecting the aortic and pulmonary vasculature.
Professor of Electrical and Systems Engineering
Barry Silverman, Ph.D. is Professor of Systems Science & Engineering at the University of Pennsylvania. His research has largely been on socio-cognitive agent models that can be useful for profiling and simulating health and well-being in actual communities and societies. These simulated worlds reflect aspects of the real world and thereby help users to analyze policies that might improve system performance. Barry is the author of over 130 articles, 1 board game, and 6 fielded, serious gameworlds. He is a Fellow of IEEE and AAAS and recipient of several research and teaching excellence awards, including a 1st place for AI/Pattern of Life in the 2011 Federal Virtual World Competition.
Associate Professor of Statistics, Wharton
Dr. Small is a statistician specializing in causal inference, observational studies, and applications to the health sciences. He is particularly interested in comparative effectiveness research and instrumental variables methods for estimating treatment effects in randomized trials with nonadherence and observational studies with unmeasured confounding.
Professor of Epidemiology & Physical Medicine and Rehabilitation
Dr. Stineman's research applies both qualitative phenomenological methods and quantitative analytic approaches to disability sciences. An expert in statistical modeling, health status, functional status, and quality of life measurement, she has served as PI on numerous NIH and AHRQ funded projects since 1990 covering a broad range of topics of relevance to people with disabilities. Areas include the development of the Functional Independent Staging approach, comorbidity measurement, outcomes assessment, effectiveness research applying various approaches to remove selection bias, environmental confounders of disability, and quality of life measurement. Work directed by Dr. Stineman has informed national and international health care policy. She was the PI on a series of projects that led to a clinical case-mix measure, which forms the basis of Medicare’s Prospective Payment System for medical rehabilitation. That measure is also used as a national performance indicator by the Department of Veterans Affairs. Dr. Stineman and her colleagues also developed a procedure referred to as Recovery Preference Exploration (RPE) designed to understand the personal meaning behind alternative disability and health states and to enhance the depth of communication between patients and clinicians.
Professor and Executive Vice Dean for Institutional Affairs, PSOM
Dr. Strom's interests span many areas of clinical epidemiology, but his major research interest is the field of pharmacoepidemiology, i.e., the application of epidemiologic methods to the study of drug use and effects. He is editor of the field's major text (now in its fifth edition), and is Editor-in-Chief for Pharmacoepidemiology and Drug Safety, the official journal of the International Society for Pharmacoepidemiology (ISPE). He is best known as a founder of the field of pharmacoepidemiology, and a pioneer in using large automated databases for research. As one of many specific contributions, his research was pivotal in getting the American Heart Association and American Dental Association to reverse 50 years of guidelines, and recommend against use of antibiotics to prevent infective endocarditis, instead of recommending for this widespread practice. Recent grants include a National Cancer Institute Program Project Grant on Molecular Susceptibility to Hormone-Induced Cancers, awards from the Agency for Health Care Research and Quality for a Center for Research and Education on Therapeutics, a Center of Excellence for Patient Safety Research and Practice, and a center within the Developing Evidence to Inform Decisions About Effectiveness (DEcIDE) Network.
Professor of Biostatistics
r. Troxel has experience with all phases of clinical trials, as well as epidemiological and basic science studies. Her research interests are in longitudinal analysis and missing data, particularly informative or nonignorable missing data, as well as in innovative designs for clinical trials. These include adaptive randomization, adaptive treatment strategies, and rapid-cycle innovation in trial design. Her collaborative interests span a wide range of topics, including oncology, dermatology, cardiovascular disease, and behavioral economics.
Assistant Professor of Medicine and Epidemiology
Dr. Umscheid is Director of the Penn Medicine Center for Evidence-based Practice, a hospital-based comparative effectiveness center funded by Penn to summarize, disseminate, and implement scientific evidence for high impact decision making. He also is Co-Director of the National Institutes of Health Clinical and Translational Science Award supported Health System Informatics Core, where he uses Penn data to measure the impact of best practices implemented at Penn through computerized clinical decision support (CDS). Outside of Penn, Dr. Umscheid collaborates with organizations including the Centers for Disease Control and Prevention (CDC) to assist with guideline development.
Research Associate Professor of Pediatrics
Dr. White is Research Associate Professor of Pediatrics and Director of the Center for Biomedical Informatics (CBMi) at CHOP. His research is in the area of genomic contributors to pediatric disease, and he has a special interest in developing and applying novel translational informatics methods for pediatric disorders. Currently, he is playing a leadership role on the Clinical Sequencing Exploratory Research (CSER) Project awarded by NHGRI to Children's Hospital of Philadelphia as PI of Project 2, “Sequencing, Analysis and Interpretation of Sequencing Data.” For that project, Dr. White and his team are building a framework for systematically assessing gene sequence data collected from children in four disease groups and developing workflows and tools within a technology infrastructure to deliver clinician guidance (through a unique clinical decision service and architecture) that is directly embedded in a patient's health record.
Assistant Professor of Biostatistics and Epidemiology
Dr. Yang's current methodological interest focuses on two topics in causal inference. One is to use semi-parametric estimating equations to estimate the effect of time-updated treatment with the proper adjustment of time-dependent confounding using observational data. Related research is how to deal with non-adherence and loss to follow-up in randomized trials. His second research focus is to extend the propensity score methodology to general treatment regimes.
Philadelphia VA Medical Center Staff Physician
Dr. Ahmad finished his internal medicine residency at the Hospital of the University of Pennsylvania in June 2012 and is planning to start cardiology fellowship in June 2013. He is interested in quality and outcomes research with a focus on cardiovascular diseases. More specifically, he is interested in models to predict hospital readmissions, strategies to reduce readmissions, and the dissemination of successful reduction strategies. His interests also include the use of health IT to improve quality and outcomes, including its role in facilitating chronic disease management, treatment adherence, and the incorporation of pharmacogenetic information via clinical decision support tools.
Adjunct Asst. Professor of Epidemiology/Sr. Research Investigator, CCEB; PhD Student, Epidemiology
Kevin Haynes completed a two-year drug development fellowship with the University of North Carolina School of Pharmacy and GlaxoSmithKline. During the second year of the fellowship, he conducted a Phase Ila clinical trial within the Cardiovascular and Urology Clinical Development and Medical Affairs Department He has conducted several comparative effectiveness research projects using local and international database resources and supports several fellows and faculty members in their ongoing comparative effectiveness research. He is pursuing a PhD and will have a large focus on comparative effectiveness.
Fellow, Infectious Diseases and Center for Healthcare Improvement and Patient Safety
As a fellow in both the University of Pennsylvania Perelman School of Medicine Division of Infectious Diseases and Center for Healthcare Improvement and Patient Safety, Dr. Keller’s focus is on improving the quality of care for patients with infectious diseases. In particular, she is studying outcomes and quality metrics of patients discharged from acute care hospitals on parenteral antimicrobials, examining both clinical outcomes and care coordination in this group of patients. Dr. Keller is part of the Infectious Diseases Transitions Service, a group that develops and studies interventions for patients transitioning to outpatient parenteral antimicrobial therapy. In addition, she is studying characteristics of HIV clinics that provide a high quality of care for patients, using data collected by the City of Philadelphia Department of Public Health AIDS Activities Coordinating Office.
Postdoctoral Fellow, Anesthesiology and Critical Care
Dr. Lane-Fall is a critical care anesthesiologist interested in processes of care for critically ill patients. Specifically, she is interested in how communication and teamwork affect care delivery in the intensive care unit (ICU). She is currently conducting studies about ICU handoffs and ICU staffing models.
Postdoctoral Research Fellow, Division of Translational Medicine and Human Genetics
Dr. Tuteja-Stevens' background is in clinical pharmacy with extensive experience in medication therapy management of solid organ transplant recipients. Dr. Tuteja-Stevens is interested in patient oriented research using genomic tools to discover genetic basis of drug response mechanisms and subsequently identify new molecular targets for therapeutic intervention. In addition, she is interested in team-based healthcare delivery models to improve medication adherence. She is currently a pharmacogenomics fellow in the laboratory of Dr. Daniel J. Rader, studying the genetic determinants of the flushing and metabolic response to acute niacin using both targeted (sequencing) and agnostic (genome-wide genotyping) approaches. She is also a fellow in the Penn Center for the Integration of Genetic Healthcare Technologies (PennCIGHT), one of six national Centers of Excellence for research on the Ethical, Legal, and Social Implications (ELSI) of genetics and the human genome. She and her colleagues within PennCIGHT are currently studying the role of pharmacists in pharmacogenetic testing, with the aim of advancing pharmacogenetic tests into clinical practice.